Matinas BioPharma appoints Evelyn D'An as independent director and Audit Committee Chair

Matinas BioPharma Holdings, Inc.

Evelyn D'An appointed to board effective February 5, 2025 as independent director and Audit Committee Chair.
Ms. D'An is a former Ernst & Young partner with 18 years of experience, currently President of D'An Financial Services.
She also serves on boards of Zoomcar (ZCAR), Backblaze (BLZE), and GHD Group (private).
No related party transactions; compensated under standard non-employee director plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.